Medinol/Gore
This article was originally published in The Gray Sheet
Executive Summary
NIRTOP randomized study of 305 patients at 15 international centers demonstrates a 6.3% restenosis rate for lesions greater than 3 mm treated with the NirFlex bare metal coronary stent. The treatment arm showed late-loss rate of 0.65 mm in addition to target vessel revascularization rates of 4.4%, 7% and 8.9% at 180 days, 210 days and 280 days, respectively. Antonio Colombo, MD, San Raffaele Hospital, Milan, Italy, served as the study's principal investigator...
You may also be interested in...
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.